 Cabaletta Bio, Inc. CABA, a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that in vivo data demonstrating specific engagement and elimination of anti-muscle-specific tyrosine kinase MuSK antibody-expressing target cells by Chimeric AutoAntibody Receptor CAAR T cells was presented at the American Academy of Neurology AAN 2020 Science Highlights Virtual Platform by the laboratory of Aimee Payne, M.D., Ph.D., Associate Professor of Dermatology in the Perelman School of Medicine at the University of Pennsylvania and co-chair of the Scientific Advisory Board and co-founder at Cabaletta Bio. The research was performed in collaboration with Kevin OConnor, Ph.D., Associate Professor of Neurology and Immunobiology at the Yale School of Medicine and an internationally recognized expert in the field of B cell-mediated autoimmune diseases, including myasthenia gravis, and was sponsored, in part, by Cabaletta Bio. 